Evaluation Of Curative Effect Of Secukinumab And Ustekinumab In The Treatment Of Moderate To Severe Plaque Psoriasis

Objective:To investigate the short-term clinical outcomes after comparing secukizumab and ustekinumab used to treat moderate-to-severe plaque psoriasis and the adverse effects that occur after the use of these two biologics.Methods:40 patients with moderate-to-severe plaque psoriasis attending the First Affiliated Hospital of Nanchang University were selected.Then the 40 patients were separated into two groups using the chaotic number table method,namely the secukizumab treatment group and the ustekinumab treatment group.There were 20 cases in the secukicizumab treatment group and 20 cases in the ustekinumab treatment group.PASI scores and DLQI scores were performed at weeks 0,4,8,12,and 16,as well as adverse effects that occurred during the treatment.Finally,the recorded data were used to compare the efficacy and safety of the drugs in both groups.Results:Ultimately,all 40 patients completed clinical observation,with an overall shedding rate of 0.00%.After statistical data analysis,a comparison of the baseline data between the two observation groups revealed that P > 0.05,indicating that there was no significant difference between the two groups prior to treatment and that the two observation groups were comparable.10 patients(50.00%)on secukinumab achieved PASI 100,16(80.00%)achieved PASI 90 and 20(100.00%)all achieved PASI 75 at week 16.PASI 75 was achieved in 3(16.00%)of patients treated with ustekinumab,PASI 100 in 9(45.00%)and PASI 75 in 15(75.00%)at week 16.at week 4,the PASI 75 response rate was significantly lower in the ustekinumab group than in the secukizumab group(p < 0.05),but At week 8,when PASI 90 was achieved in the comparison patients,the ustekinumab group(15.00%)had a significantly lower response rate than the secukizumab group(55.00%,p=0.02(p<0.05)).At week 12 when comparing patients reaching PASI 100,it was still seen that the secukizumab group(40.00%)was higher than the ustekinumab group(5.00%,P=0.023(P<0.05)).Finally,a comparison of PASI 75 response rates at week 16 showed only 75.00% in the ustekinumab group compared to 100.00% in the secukizumab group(P=0.407(P<0.05));a comparison of PASI 100 response rates showed that 50.00% of patients on secukizumab achieved PASI 100 compared to only 3 patients(15.00%)in the ustekinumab group patients achieved PASI 100(p=0.043(p<0.05)).The number of patients treated with secukizumab who achieved DLQI 0/1 after weeks 4,8,12 and16 was 7(35.00%),12(60.00%),13(65.00%)and 15(75.00%),respectively,while the number of patients treated with ustekinumab who achieved DLQI 0/1 after weeks4,8,12 and 16 was 1(5.00%),4 cases(20.00%),7 cases(35.00%)and 9 cases(45.00%)respectively.There was one(5.00%)adverse reaction of eczema-like rash with secukinumab and one(5.00%)adverse reaction of nasopharyngitis in the ustekinumab group..Conclusion:In this small sample observation trial,both secukizumab and ustekinumab were found to basically control clinical symptoms,reduce inflammatory response and improve quality of life.Secondly,the short-term efficacy of secukizumab was significantly better than that of ustekinumab in the treatment of moderate-to-severe plaque psoriasis,and both of them did not show serious adverse effects and had high safety.